糖尿病视网膜病变联合玻璃体腔药物注射治疗新进展  

Recent Progress in Intravitreal Injection of Drug for Diabetic Retinopathy

作　　者：陈世久 秦梅[1] 

机构地区：[1]蚌埠医学院第一附属医院眼科,安徽蚌埠233000

出　　处：《医学综述》2015年第17期3188-3191,共4页Medical Recapitulate

摘　　要：随着人们生活水平提高,糖尿病患者日益增多,糖尿病视网膜病变(DR)发病率也越来越高。以往对于DR通常单独采用激光光凝治疗,治疗效果较好,但并不能有效提高患者的视力。随着近年来药物应用的新发展,抗血管内皮生长因子和其他相关药物,如曲安奈德等已被应用于DR的治疗,并且取得良好的疗效。该文对近几年国内外对DR玻璃体腔药物注射治疗的最新进展予以综述。Now there are more and more people suffering from diabetic retinopathy（DR） along with the increase of diabetic patients. Laser photocoagulation therapy was usually used to treat DR alone, which had good therapeutic effect,but could not improve the patient＇s vision. With the development of the drug applica- tion;the anti-vascular endothelial growth factor drugs and other related drugs have been used to treat DR, and they have already achieved good curative effect. Here is to make a review of the new progress in iutravitreal injection of drug for.

关 键 词：糖尿病视网膜病变 抗血管内皮生长因子药物 药物安全性 曲安奈德 

分 类 号：R774.1[医药卫生—眼科]